Dr. Ethan Balkin

Program Manager, Radioisotope R&D, Office of Isotope R&D and Production, U.S. Department of Energy

Astatine and the DOE Isotope Program

ABSTRACT

The presentation will cover the history of the DOE Isotope Program’s role in the domestic U.S. production of At-211. Dr. Balkin will also provide the current state of the DOE IP University Isotope Network, it’s role within the World Astatine Community, and plans concerning At-211.

SPEAKER BIO

Dr. Ethan Balkin is the Federal Program Manager for Radioisotope Research and Development (R&D) in the U.S. Department of Energy’s Isotope Program (DOE IP). He is responsible for all DOE IP efforts in workforce development and radioisotope R&D. Prior to joining DOE IP, Dr. Balkin was a Professor of Radiation Oncology at the University of Washington, where he worked on solid target chemistry for the cyclotron-based production of isotopes, as well as the development of bioconjugation and radiolabeling techniques for monoclonal antibodies and novel small molecules used primarily in heme-based malignancies. He also did his postdoctoral training there.

Dr. Balkin completed his undergraduate work with a research focus in radioanalytical chemistry, and his doctorate in pathobiology with an emphasis in targeted radiopharmaceutical therapy and rational drug design; both at the University of Missouri-Columbia. In between his undergraduate and graduate degrees, Dr. Balkin spent two years working in drug development focusing on critical-care pediatrics at the University of Missouri-Columbia Department of General Surgery.

Return to conference agenda